By: Benzinga
Merck Sues to Stop Generic NuvaRing
Merck (NYSE: MRK ) is suing Actavis (NYSE: ACT ) in an attempt to keep a generic version of its profitable NuvaRing birth control device off the market, Bloomberg reported . Merck is accusing Warner Chilcott, a division of Actavis, of violating its patent on NuvaRing. Actavis has announced
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here